CAJ | 학술논문

目的观察紫杉醇联合羟基喜树碱治疗晚期食管癌的近远期疗效和不良反应.方法 70例晚期食管癌患者随机被分为PH组和NP组,PH组采用紫杉醇联合羟基喜树碱治疗,NP组采用长春瑞滨联合顺铂治疗方案,评价2组疗效和不良反应.结果 ①PH组有效率为47.1%,疾病控制率73.5%;NP方案有效率为43.3%,疾病控制率63.3%,2组比较差异无统计学意义(P>0.05).②PH组患者生存率为29.4%,死亡率为70.6%;NP组生存率为26.7%,死亡率为73.3%,2组远期疗效比较差异无统计学意义(P>0.05).③2组均出现严重的白细胞减少和脱发现象,发生率>90%,但PH组Ⅲ～Ⅳ级发生率显著低于NP组(P<0.05);PH组出现关节肌肉痛和恶心呕吐的发生率和Ⅲ～Ⅳ级发生率均显著低于NP组(P<0.05).结论紫杉醇联合羟基喜树碱治疗晚期食道癌疗效确切,毒性反应可耐受,值得进一步临床应用和观察.
목적 관찰자삼순연합간기희수감치료만기식관암적근원기료효화불량반응.방법 70례만기식관암환자수궤피분위PH조화NP조,PH조채용자삼순연합간기희수감치료,NP조채용장춘서빈연합순박치료방안,평개2조료효화불량반응.결과 ①PH조유효솔위47.1%,질병공제솔73.5%;NP방안유효솔위43.3%,질병공제솔63.3%,2조비교차이무통계학의의(P>0.05).②PH조환자생존솔위29.4%,사망솔위70.6%;NP조생존솔위26.7%,사망솔위73.3%,2조원기료효비교차이무통계학의의(P>0.05).③2조균출현엄중적백세포감소화탈발현상,발생솔>90%,단PH조Ⅲ～Ⅳ급발생솔현저저우NP조(P<0.05);PH조출현관절기육통화악심구토적발생솔화Ⅲ～Ⅳ급발생솔균현저저우NP조(P<0.05).결론 자삼순연합간기희수감치료만기식도암료효학절,독성반응가내수,치득진일보림상응용화관찰.
Objective To observe the clinical therapeutic effect and safety of Paclitaxel combined with Hydroxycamptothecin(HCPT) in treatment of advanced esophageal cancer. Methods 70 cases of advanced esophageal cancer patients were randomly divided into PH group and NP group. PH group was given treatment of Paclitaxel combined with HCPT, while the NP group was given treatment of NVB combined with DDP.The clinical therapeutic 47.1%, disease control rate of 73.5%;NP group had efficiency of 43.3%, disease control rate of 63.3%, there was no significant difference(P>0.05) 70.6%; NP group survival rate was 26.7%, mortality rate was 73.3%,there there were serious leukopenia and hair loss situation,the incidence was>90%,but the PH group Ⅲ～Ⅳ level incidence was significantly lower than the NP group(P<0.05);PH group the incidence and grade Ⅲ～Ⅳ incidence of joint muscle pain,nausea and vomiting were significantly lower than the control group(P<0.05).Conclusion Paclitaxel combined with HCPT in treatment of advanced esophageal cancer is effective,adverse reactions can be tolerated,and it is worth further clinical research and extension.